Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Clean Yield Group

Clean Yield Group trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 30.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,140 shares of the biopharmaceutical company’s stock after selling 12,638 shares during the quarter. Clean Yield Group’s holdings in Gilead Sciences were worth $1,841,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Malaga Cove Capital LLC lifted its stake in shares of Gilead Sciences by 0.6% during the 2nd quarter. Malaga Cove Capital LLC now owns 24,813 shares of the biopharmaceutical company’s stock worth $1,909,000 after buying an additional 143 shares during the last quarter. Anderson Fisher LLC increased its holdings in Gilead Sciences by 0.9% in the 2nd quarter. Anderson Fisher LLC now owns 17,237 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 149 shares during the period. Archford Capital Strategies LLC increased its holdings in Gilead Sciences by 1.5% in the 2nd quarter. Archford Capital Strategies LLC now owns 9,912 shares of the biopharmaceutical company’s stock valued at $763,000 after buying an additional 149 shares during the period. Exchange Capital Management Inc. increased its holdings in Gilead Sciences by 1.2% in the 2nd quarter. Exchange Capital Management Inc. now owns 12,670 shares of the biopharmaceutical company’s stock valued at $975,000 after buying an additional 150 shares during the period. Finally, Global Wealth Management Investment Advisory Inc. increased its holdings in Gilead Sciences by 66.5% in the 2nd quarter. Global Wealth Management Investment Advisory Inc. now owns 388 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 155 shares during the period. 77.87% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ GILD traded down $0.96 during trading on Friday, hitting $62.00. The stock had a trading volume of 12,307,196 shares, compared to its average volume of 14,747,112. Gilead Sciences, Inc. has a 12 month low of $61.65 and a 12 month high of $85.97. The company has a debt-to-equity ratio of 1.22, a current ratio of 2.33 and a quick ratio of 2.23. The company has a market capitalization of $77.73 billion, a PE ratio of -258.32, a PEG ratio of 0.74 and a beta of 0.55. The firm has a fifty day moving average of $64.31 and a two-hundred day moving average of $72.31.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.57 by ($0.46). Gilead Sciences had a positive return on equity of 33.59% and a negative net margin of 1.16%. The firm had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.24 billion. On average, equities analysts expect that Gilead Sciences, Inc. will post 6.85 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th were paid a $0.68 dividend. The ex-dividend date was Monday, September 14th. This represents a $2.72 annualized dividend and a dividend yield of 4.39%. Gilead Sciences’s payout ratio is 44.30%.

A number of brokerages have recently issued reports on GILD. Piper Sandler dropped their price target on shares of Gilead Sciences from $85.00 to $83.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 19th. Jefferies Financial Group began coverage on shares of Gilead Sciences in a research report on Wednesday, September 30th. They set a “buy” rating and a $78.00 target price on the stock. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Gilead Sciences in a research report on Friday, August 7th. Credit Suisse Group dropped their target price on shares of Gilead Sciences from $75.00 to $73.00 and set a “neutral” rating on the stock in a research report on Friday, July 31st. Finally, Oppenheimer boosted their target price on shares of Gilead Sciences from $90.00 to $105.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $78.93.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: Stochastic Momentum Index (SMI)

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.